Measured by its ability to induce activin-responsive firefly luciferase reporter activity in HepG2 cells. The EC50 for this effect is typically 0.59-1.2 ng/ml.
Product Details
Product Details
Product Specification
| Species | Human, Mouse, Rat |
| Synonyms | Inhibin beta A chain; Activin beta-A chain; Erythroid differentiation protein (EDF); |
| Accession | P08476 |
| Amino Acid Sequence | Gly311-Ser426, F368A |
| Expression System | CHO |
| Molecular Weight | 12-14 kDa (Reducing) |
| Purity | >95% by SDS-PAGE,>90% by HPLC |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | 4mM HCl |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in reconstitution buffer (4mM HCl) after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16239-44. |
Background
Activin A is a dimeric glycoprotein belonging to the transforming growth factor-beta (TGF-β) superfamily of cytokines. It is involved in various biological processes, including embryonic development, reproductive function, and regulation of the immune system. Activin A is produced by a wide range of cell types, including immune cells, endothelial cells, and reproductive tissues. It exerts its effects by binding to the activin type II receptors, leading to the activation of downstream signaling pathways involved in cell proliferation, differentiation, and immune modulation. Activin A has been implicated in the regulation of inflammation, tissue repair, and the pathogenesis of various diseases, including cancer and autoimmune disorders.
Picture
Picture
Bioactivity

SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
RP-HPLC
>95% as determined by RP-HPLC.
